KRONOS BIO INC (KRON) Stock News

NASDAQ:KRON - Nasdaq - US50107A1043 - Common Stock - Currency: USD

0.88 +0.01 (+1.49%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

KRON Latest News, Press Relases and Analysis

All

Press Releases

2 months ago - By: Benzinga - Mentions: CYCC RGNX HSDT EYEN ...

12 Health Care Stocks Moving In Thursday's Intraday Session

2 months ago - By: Benzinga - Mentions: RGC APDN SNTI HSDT ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

2 months ago - By: Halper Sadeh LLC - Mentions: AXL PRA SWTX

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AXL, KRON, PRA, SWTX on Behalf of Shareholders

3 months ago - By: Halper Sadeh LLC - Mentions: SSBK RGLS XAGE

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders

3 months ago - By: Brodsky & Smith LLC - Mentions: SSBK RGLS XAGE

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (Nasdaq - KRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Longevity Health Holdings, Inc. (Nasdaq - XAGE), Southern States Bancshares, Inc. (Nasdaq

3 months ago - By: Kahn Swick & Foti, LLC

KRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc. - KRON

3 months ago - By: Halper Sadeh LLC - Mentions: DNB COLB

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DNB, COLB, KRON on Behalf of Shareholders

3 months ago - By: Brodsky & Smith LLC - Mentions: RGLS COEP PPBI COLB

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (Nasdaq - KRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Coeptis Therapeutics Holdings, Inc. (Nasdaq – COEP), Pacific Premier Bancorp, Inc.

3 months ago - By: Ademi & Fruchter LLP

Shareholder Alert: The Ademi Firm Investigates Whether Kronos Bio, Inc. is Obtaining a Fair Price for Its Public Shareholders

3 months ago - By: Halper Sadeh LLC

KRON Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kronos Bio, Inc. Is Fair to Shareholders

3 months ago - By: Kronos Bio, Inc.

Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right

3 months ago - By: Kronos Bio, Inc.

Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right

4 months ago - By: Kronos Bio, Inc.

Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results

4 months ago - By: Kronos Bio, Inc.

Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results

8 months ago - By: Kronos Bio, Inc.

Kronos Bio Announces CEO Transition and Reduction in Force

8 months ago - By: Kronos Bio, Inc.

Kronos Bio Announces CEO Transition and Reduction in Force

9 months ago - By: Kronos Bio, Inc.

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

9 months ago - By: Kronos Bio, Inc.

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

9 months ago - By: Kronos Bio, Inc.

Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives

9 months ago - By: Kronos Bio, Inc.

Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives

9 months ago - By: Kronos Bio, Inc.

Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma

9 months ago - By: Kronos Bio, Inc.

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors

9 months ago - By: Kronos Bio, Inc.

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors

10 months ago - By: Kronos Bio, Inc.

Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors

10 months ago - By: Kronos Bio, Inc.

Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors

10 months ago - By: Kronos Bio, Inc.

Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease

10 months ago - By: Kronos Bio, Inc.

Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease